Graduation policy

in page functions

Countries whose Gross National Income (GNI) per capita crosses the Gavi eligibility threshold (currently US$ 1,580) enter a graduation process and start phasing out of Gavi support. During this period, Gavi will intensify its efforts to help graduating countries be in the best position to financially sustain their routine programmes and new vaccines.

Support for a previously eligible country does not end abruptly as existing multi-year commitments for vaccines and/or cash-based programmes from Gavi will continue to be honoured. In November 2013 the Gavi Board approved a strengthened approach to graduation according to which countries entering graduation now have an additional year to apply for Gavi new vaccine support and are entitled to apply for health system strengthening (HSS) support for the duration of their graduation period, if their DTP3 coverage is below 90%.

What is the purpose of Gavi's graduation policy?

This policy sets out the process and procedures for "graduation".

Download the policy

When is the policy applied and how does it work?

The policy is applied to countries whose per capita income exceeds the Gavi eligibility threshold. Key issues set out by the policy include:

  • Gavi will inform the country that it has entered the graduation process and spell out in detail what this entails.
  • Subject to availability of funding, Gavi will honour all existing Board-approved multi-year commitments to countries in the graduation process for the duration of current multi-year plans.
  • If subsequent to graduation a country's GNI per capita falls below the eligibility threshold, the country would regain its Gavi-eligible status.

When was the current policy approved and when will it be updated?

The graduation policy was approved by the Gavi Board in November 2009 and came into effect at the start of 2011. The policy is scheduled for review and, if required, updating in 2015.

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here